Search research articles
Contact Us
Filters
Showing results (171-180 of 2,246) with videos related to
Page
of 225
Sort By:
ESMO Open
|
October 26, 2024
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
M H Hong, S Park, T Vo, et al.
ESMO Open
|
October 26, 2024
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
J Wang, S Lu, X Yu, et al.
ESMO Open
|
March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
R Cohen, M Raeisi, B Chibaudel, et al.
ESMO Open
|
August 7, 2024
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
L Guidi, C Valenza, E Battaiotto, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
ESMO Open
|
August 31, 2024
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer
C I Ripamonti, C Chelazzi
ESMO Open
|
August 30, 2024
PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
T A Yap, A D Choudhury, E Hamilton, et al.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
ESMO Open
|
August 9, 2024
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
F Poggio, E Blondeaux, M Tagliamento, et al.
ESMO Open
|
August 13, 2024
Bioimpedance-derived body composition parameters predict mortality and dose-limiting toxicity: the multicenter ONCO-BIVA study
E Cereda, A Casirati, C Klersy, et al.
Page
of 225
Search research articles
Search
Showing results (171-180 of 2,246) with videos related to
Sort By:
Page
of 225
ESMO Open
|
October 26, 2024
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
M H Hong, S Park, T Vo, et al.
ESMO Open
|
October 26, 2024
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
J Wang, S Lu, X Yu, et al.
ESMO Open
|
March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
R Cohen, M Raeisi, B Chibaudel, et al.
ESMO Open
|
August 7, 2024
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
L Guidi, C Valenza, E Battaiotto, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
ESMO Open
|
August 31, 2024
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer
C I Ripamonti, C Chelazzi
ESMO Open
|
August 30, 2024
PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
T A Yap, A D Choudhury, E Hamilton, et al.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
ESMO Open
|
August 9, 2024
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
F Poggio, E Blondeaux, M Tagliamento, et al.
ESMO Open
|
August 13, 2024
Bioimpedance-derived body composition parameters predict mortality and dose-limiting toxicity: the multicenter ONCO-BIVA study
E Cereda, A Casirati, C Klersy, et al.
Page
of 225